Current and potential pharmacological treatments for obsessive-compulsive disorder

  title={Current and potential pharmacological treatments for obsessive-compulsive disorder},
  author={Joyce D. Davidson and Throstur Bjorgvinsson},
  journal={Expert Opinion on Investigational Drugs},
  pages={1001 - 993}
In the past 20 years, several effective treatments have been developed for obsessive-compulsive disorder. Despite this, it is a disorder that is often inadequately treated by available therapies. Recent advances in neuroimaging and neurophysiology have provided some clues to possible treatments that may be more effective in treating this disorder. Serotonin agents remain the cornerstone of pharmacological treatment for obsessive-compulsive disorder. The development of agents that target… Expand
Obsessive-compulsive disorder (OCD) is an anxiety disorder characterized by uncontrollable, unwanted thoughts and repetitive, ritualized behaviours. It is a good example for neuropsychiatricExpand
Glutamatergic dysfunction--newer targets for anti-obsessional drugs.
The rationale for targeting glutamatergic agents as well as the recent important patents for compounds that have emerged from these studies are focused on. Expand
Role of serotonin in obsessive-compulsive disorder
Evidence supporting a role for the serotonin transporter and serotonin receptor subtypes in the pathophysiology and treatment of OCD is summarized. Expand
Obsessive-Compulsive Disorder: Update on Assessment and Treatment
The assessment of OCD can be guided by using published semi-structured interview tools, including a standardized symptom checklist and severity rating scale, and the cognitive-behavioral assessment and treatment approach is provided. Expand
The serotonergic system in obsessive-compulsive disorder.
Abstract Obsessive-compulsive disorder (OCD) is a psychiatric disorder consisting of obsessions and compulsions. Over the past two decades it has been suggested that OCD might be related to theExpand
The neuropsychology of obsessive compulsive disorder: the importance of failures in cognitive and behavioural inhibition as candidate endophenotypic markers
It is proposed that neurocognitive indices of inhibitory functions may represent a useful heuristic in the search for endophenotypes in OCD, and that failures in cognitive and behavioural inhibitory processes appear to underlie many of the symptoms and neuroc cognitive findings. Expand
Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application.
  • M. Millan
  • Medicine
  • Pharmacology & therapeutics
  • 2006
A diversity of multi-target strategies are proposed for the more efficacious and rapid control of core and co-morbid symptoms of depression, together with improved tolerance relative to currently available agents. Expand
Effects of agents targeting glutamatergic systems on marble-burying behavior
The present results suggest that glutamatergic systems might be related to marble-burying behavior and agents targeting glutamaters, such as an AMPA receptor potentiator and an NR2B receptor antagonist, may be useful in treating OCD. Expand


Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review.
  • J. Abramowitz
  • Psychology, Medicine
  • Journal of consulting and clinical psychology
  • 1997
Quantitative review of the controlled treatment outcome literature for obsessive-compulsive disorder (OCD) showed that exposure with response prevention was highly effective in reducing OCD symptoms.Expand
Treatment of severe obsessive-compulsive disorder with fluvoxamine.
Fluvoxamine appears effective in treating severe obsessive-compulsive disorder, as measured by several clinical scales and self-ratings. Expand
Exposure with response prevention and serotonergic antidepressants in the treatment of obsessive compulsive disorder: a review and implications for interdisciplinary treatment.
  • J. L. Abel
  • Psychology, Medicine
  • Behaviour research and therapy
  • 1993
Findings suggested that ERP is more effective than CMI, particularly in alleviating rituals, but CMI may be more effective in reducing obsessive compulsive behavior among individuals with concomitant severe depression, obsessions only, and overvalued ideation. Expand
Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.
The authors found that buspirone added to the treatment of 33 patients with obsessive-compulsive disorder who were refractory to the serotonin reuptake inhibitor fluvoxamine was no better thanExpand
Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder.
It is suggested that clozapine monotherapy is not effective for most adult patients with treatment-resistant obsessive-compulsive disorder. Expand
Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
The results of this preliminary, open-label trial suggest that olanzapine may be effective in augmenting ongoing SSRIs treatment for a portion of patients with obsessive-compulsive disorder refractory to SSRI treatment. Expand
Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
Antidepressant drugs are effective in the short-term treatment of patients suffering from OCD; although the increase in improvement rate over placebo was greater for clomipramine than for SSRIs, direct comparison between these drugs showed that they had similar therapeutic efficacy on obsessive-compulsive symptoms. Expand
Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder
Although limited by the retrospective design and lack of controls, these data are consistent with the growing literature suggesting that approximately one-half of OCD patients resistant to treatment with SRIs may respond to augmentation with an atypical antipsychotic. Expand
Open trial of fluoxetine in obsessive-compulsive disorder.
A 12-week open trial of fluoxetine in 61 obsessive-compulsive disorder patients significantly improved depressive and obsessive- compulsive symptoms and reinforced the hypothesis of serotonergic abnormalities in obsessive-Compulsive disorder. Expand
Quetiapine augmentation in patients with treatment resistant obsessive–compulsive disorder: a single-blind, placebo-controlled study
The addition of quetiapine to ongoing SRI therapy has been found to be effective and well-tolerated approach in patients with refractory OCD. Expand